Health
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine – GlobeNewswire
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection …
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection
Supports the Development of New Approaches to Treat Multiple Neurological Diseases
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) — CytoDel, Inc. (CytoDel or the Company), a privately-held corporation, today announces the publication of preclinical data on the Companys lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine….
-
Noosa News22 hours agoMan allegedly killed at teenage house party identified as co-founder of Universal Store
-
Noosa News23 hours agoRising talent shine at Noosa International Surfilm Festival 2025
-
Noosa News24 hours agoSearch for missing man after unattended dinghy found near Boondooma Dam in Proston, QLD
-
Business24 hours agoSuncorp shares push higher on big leadership news